Presence of Anti-drug Antibodies Does Not Reduce the Efficacy of an Oral Anti-TNF Antibody in a Murine IBD Model

被引：0
|
作者：
Bhol, Kailash [1 ]
Erlich, Emma [1 ]
Lemos, Brenda [1 ]
Tracey, Daniel [1 ]
Hartman, Deborah [1 ]
Fox, Barbara [1 ]
机构：
[1] Avaxia Biol Inc, Lexington, MA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2013年 / 108卷
关键词：
D O I：
10.14309/00000434-201310001-01810
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1810
引用
收藏
页码：S545 / S546
页数：2
相关论文
共 50 条
  • [1] LOW DRUG CONCENTRATIONS AND ANTI-DRUG ANTIBODY FORMATION TO THE PRIOR ANTI-TNF PREDISPOSES PATIENTS WITH INFLAMMATORY BOWEL DISEASE TO DEVELOP ANTI-DRUG ANTIBODIES TO THE SUBSEQUENT ANTI-TNF
    Cheifetz, Adam S.
    Abreu, Maria T.
    Flier, Sarah N.
    Papamichail, Konstantinos
    Rieder, Florian
    Silverberg, Mark S.
    Khanna, Reena
    Okada, Lauren
    Yang, Lei
    Jain, Anjali
    Vande Casteele, Niels
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S457 - S457
  • [2] Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
    C. C. Mok
    D. van der Kleij
    G. J. Wolbink
    [J]. Clinical Rheumatology, 2013, 32 : 1429 - 1435
  • [3] ANTI-DRUG ANTIBODIES, DRUG LEVELS AND CLINICAL EFFICACY OF THE ANTI-TNF BIOLOGICS IN RHEUMATIC DISEASES
    Mok, C. C.
    van der Kleij, D.
    Wolbink, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 226 - 226
  • [4] Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
    Mok, C. C.
    van der Kleij, D.
    Wolbink, G. J.
    [J]. CLINICAL RHEUMATOLOGY, 2013, 32 (10) : 1429 - 1435
  • [5] SWITCHING OUT OF CLASS OR TO ANOTHER ANTI-TNF AGENT IS THE BEST STRATEGY FOR CLINICAL EFFICACY AND TREATMENT PERSISTENCE IN IBD PATIENTS WITH ANTI-DRUG ANTIBODIES AGAINST ANTI-TNF
    Anjie, Suzanne I.
    Hanzel, Jurij
    Gecse, Krisztina B.
    D'Haens, Geert
    Brandse, Johannan F.
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S1120 - S1121
  • [6] INCREASED RISK OF ANTI-DRUG ANTIBODIES TO A SECOND ANTI-TNF IN PATIENTS WHO DEVELOPED ANTIBODIES TO THE FIRST ANTI-TNF
    Yanai, Henit A.
    Amir, Shira
    Avni-Biron, Irit
    Perets, Tsachi Tsadok
    Shamir, Raanan
    Dotan, Iris
    Assa, Amit
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S671 - S671
  • [7] Increased risk of anti-drug antibodies to a second anti-TNF in patients who developed antibodies to the first anti-TNF
    Yanai, H.
    Amir, S.
    Biron, I. Avni
    Perets, T. Tsadok
    Shamir, R.
    Dotan, I.
    Assa, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S439 - S439
  • [8] Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients
    Colman, Ruben J.
    Portocarrero-Castillo, Andrea
    Chona, Deepika
    Hellmann, Jennifer
    Minar, Phillip
    Rosen, Michael J.
    [J]. INFLAMMATORY BOWEL DISEASES, 2021, 27 (04) : 507 - 515
  • [9] ANTI-DRUG ANTIBODIES AS A PREDICTOR FOR THE DISCONTINUATION OF ANTI-TNF AGENTS IN PATIENTS WITH SPONDYLOARTHRTIS
    Kim, H. J.
    Hwang, J.
    Kim, I.
    Jeong, H.
    Lee, J.
    Jeon, C. H.
    Koh, E. -M.
    Cha, H. -S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 717 - 718
  • [10] ANTI-DRUG ANTIBODIES: ASSAY PERFORMANCE IN PATIENTS TREATED WITH ANTI-TNF BIODRUGS
    Hock, B.
    O'donnell, J. L.
    Liu, J.
    Keating, P.
    Spellerberg, M.
    Stamp, L.
    Barclay, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1415 - 1415
12345